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Comparative Genomic Hybridization Analysis of Human 
Sarcomas: I. Occurrence of Genomic Imbalances and Identification 
of a Novel Major Amplicon at Iq21—q22 in Soft Tissue Sarcomas
Anne Forus, Daniël Olde Weghuis, Dominique Smeets, Oystein Fodstad, Ola Myklebost, and Ad Geurts van Kessel
Department of Human Genetics, University Hospital, Nijmegen, The Netherlands (A.F., D.O.W., D.S., A.G.v.K.); Department of 
Tumor Biology, The Norwegian Radium Hospital, Oslo, Norway (A.F., 0.F., O.M.)
Comparative genomic hybridization (CGH) was recently developed as a too! to survey entire genomes for variations in D N A  
sequence copy numbers. W e have applied this technique to detect and map amplified regions ín 54 soft tissue sarcomas. 
Aberrations were detected by visual analysis of hybridizations or contrast-enhanced digital images, followed by quantitative 
digital ratio imaging of the aberrant chromosomes. Several tumors showed increased D N A  sequence copy number at 12q I4, 
as expected. However, CGH analysis detected amplification of 12ql4 also in some tumors where neither MDM2  nor CDK4 was 
amplified, suggesting that another as yet unknown gene(s) may drive amplification of this region in sarcomas. Furthermore, a 
novel recurring amplicon was detected at I q2l-q22. D N A  amplifications coinciding with this segment were as frequent as those 
observed for I2ql4, indicating that Iq21-q22-linked gene(s) may also play an important role in the development and/or 
progression of human soft tissue sarcomas. Genes Chromosom Cancer 14:8-14 (1995). © 1995 Wiley-Uss, Inc.
INTRODUCTION
The term soft tissue sarcoma (STS) is used to 
describe a heterogeneous group of malignant tu­
mors of various supportive tissues. These tumors 
account for 1% of all human malignancies and in­
clude leiomyosarcomas, liposarcomas, angiosarco­
mas, rhabdomyosarcomas, and the most common 
form, malignant fibrous histiocytomas (MFH; En- 
zinger and Weiss, 1988). Cytogenetic studies have 
revealed structural anomalies in several STS sub­
groups (Mitelman, 1991; Sandberg and Bridge, 
1994). In fact» most of the sarcoma types have 
been shown to be characterized by recurrent 
specific chromosomal translocations (Sreekantaiah 
et al., 1994). Cytogenetic studies of many STS, 
e.g., MFH and well-differentiated liposarcomas 
(WDLPS), have demonstrated the occurrence of 
double minutes, ring chromosomes, and large rod­
shaped markers generally associated with gene am­
plifications (Meltzer et al., 1986; Dal-Cin et al., 
1993; Pedeutour et al., 1994),
Overexpression of cellular oncogenes may be an 
important factor in the development of malignant 
tumors (Slamon et alM 1989; Dati et ah, 1991). 
Such overexpression can be brought about by var­
ious mechanisms, including gene amplification. In 
soft tissue sarcomas, amplification of the MYC  on-
et al., 1993; Smith et al., 1993). Because the mdm2
protein probably inactivates the tumor suppressor 
protein p53, a selective growth advantage via 
12q 13~q 14 amplifications was first attributed to in­
creased copy numbers and expression levels o f the 
AÍDM2 gene (Momand et al., 1992; Oliner et al.,
1992). However, more recent studies have shown 
that MDM2 is not always included in the ampli- 
cons, suggesting that alternative selection mecha­
nisms may be involved (Forus et al., 1993, 1994).
Comparative genomic hybridization (CGH) al­
lows the detection of D N A -sequence copy number 
variations in tumor cells and overcomes the need 
for specific probes or previous knowledge of the 
presence and nature of chromosomal aberrations 
(Kallioniemi et al., 1992, 1994b). We have used 
this technique to map regions of amplification in 54 
soft tissue sarcomas. Our studies revealed amplifi­
cation of various chromosomal regions not previ­
ously associated with the development of these tu­




Tumor material was obtained from 45 patients
cogene has been reported by several investigators with sarcomas of various subtypes and from nine 
(Ozaki et al., 1993; Barrios et al., 1994). Also, pu­
tative oncogenes in the 1 2 q l3 -q l4  chromosome 
region are amplified in a substantial number of
cases (Oliner et al., 1992; Forus et ah, 1993; Leach
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different sarcoma samples grown subcutaneously as 
xenografts in nude mice (Table 1). T he xenografts 
have been passaged several times, and some of 
them have existed as xenograft lines for years. T he  
tissues were cut into small pieces, frozen in liquid 
nitrogen immediately after surgery, and stored at 
— 70°C. Blood samples obtained from 10 healthy 
men and women were used as controls. Peripheral 
blood from a healthy 46,XX woman was used as a 
reference in all the experiments.
4
Preparation of DNA
Genomic D N A  from tumor tissues and periph­
eral blood cells was isolated by standard methods as 
described previously (Forus et al., 1993).
Comparative Genomic In Situ Hybridization
We used a commercially available nick-transla- 
tion system (Gibco Life Technologies) to label ge­
nomic DNAs with digoxygenin-ll-dUTP (Boeh- 
ringer Mannheim) for tumor DNA and biotin-14- 
dATP (Gibco) for reference DNA. DN A fragment 
lengths can be increased by adjusting the ratio of 
D N ase to DNA  polymerase in the nick-translation 
reaction (Kallioniemi et al., 1994b). Currently, we 
add 6 units extra of the DNA polymerase I large 
fragment (Klenow). Subsequently, equal amounts 
(250-400  ng) of each of the labeled probes and 
fifty-told excess of Cot-1 DNA  were coprecipitated 
using ethanol. T he DNA was dissolved in 12 jxl of 
hybridization buffer (50% v/v formamide, 10% w/v 
dextran sulphate, 2 x  SSC, 1% v/v Tween-20, pH 
7), denatured at 80°C for 10 min, and preannealed 
at 37°C for 30 min. Finally, this mixture was used 
for hybridization to denatured normal metaphase 
spreads.
Before hybridization, slides were denatured for 3 
min at 70-74°C in 70% formamide/2x SSC, fol­
lowed by proteinase K digestion for 7.5 min at 
room temperature (0.1 fxg/ml proteinase K in 20 
mM Tris-HCl/2 mM CaCl). This treatment will 
maximize dénaturation and probe penetration but 
allows the banding pattern necessary for chromo­
some identification to remain intact (Kallioniemi et 
al., 1994b). Hybridization was carried out under a 
coverslip in a moist chamber for 2 -4  days.
After hybridization, the slides were washed ac­
cording to regular fluorescence in situ hybridiza­
tion (FISH) protocols (Pinkel et al., 1988). Immu- 
nohistochemical detection of the hybridizing 
probes was carried out as follows. For detection of 
biotin molecules, we used fluorescein isothiocy- 
anate (FITC)-conjugated avidin (dilution 1:500; 
Vector Laboratories), followed by two amplifica­
tion steps using rabbit anti-FITC (dilution 1:250; 
Dakopats) and FITC-conjugated mouse anti-rabbit 
(dilution 1:100; Jackson Immunoresearch). Digox- 
ygenin-labeled DNA was visualized after incuba­
tions with rhodamine-conjugated sheep anti-digox- 
ygenin (dilution 1:20; Boehringer Mannheim) and 
Texas red-conjugated donkey anti-sheep (dilution 
1:50; Jackson Immunoresearch). Afterwards, the 
preparations were counterstained with an antifade 
solution supplemented with 0.5 mg/ml 4,6-di- 
amino-2-phenylindole (DAPI).
Evaluation of CGH Results
For visual examination of chromosome prepara­
tions, we used a Zeiss Axiophot epifluorescence 
microscope, equipped with appropriate filters for 
visualization of FITC, Texas red, and DAPI fluo­
rescence. Digital images were recorded and pro­
cessed as described previously (Suijkerbuijk et al., 
1994a,b). Photographs were made from the com­
puter screen on Kodak EPP 100 Plus color slide 
film using a Polaroid Quick Print.
Results of CGH experiments were analyzed us­
ing the Comparative Genomic Hybridization appli­
cations within the BDS-image FISH software (On- 
cor). These applications allow a pseudocolor 
reproduction of fluorescence ratios of Texas red 
(tumor DNA hybridization pattern) and fluores­
cein (normal reference DNA hybridization pattern) 
along the chromosomes. Aberrations were first 
screened based on visual analysis of hybridization 
or contrast-enhanced digital images. For each sam­
ple, at least 10 metaphase spreads were studied. 
Increases that were not systematically present in all 
metaphases or that were seen in only one chroma­
tid or in only one of the chromosome homologs 
were considered nonspecific and were excluded 
from the analysis. Chromosome homologs showing 
regions of consistent overrepresentation of tumor 
DNA were subjected to further digital analysis, al­
lowing the generation of fluorescence intensity 
profiles for each fluorochrome along the chromo­
some. The average green to red ratio was equili­
brated to 1 in regions of normal sequence copy 
numbers. Higher ratios (peaks in the red profile) 
were interpreted as amplifications. Identification 
of the individual chromosomes and localization of 
the amplified regions were based on computer im­
ages obtained from the DAPI-banded metaphase 
chromosomes. To exclude the possibility of misin­
terpreting variations in pericentromeric and hetero- 
chromatic regions as amplifications (Kallioniemi et 
al., 1994b), we also analyzed DNA obtained from
10 healthy individuals. Regions of interindividual
IO FORUS ET AL







Malignant fibrous histiocytoma 
Malignant schwannoma
aFor each subgroup, the numbers of sarcomas examined and the samples 
with amplification of any chromosomal region are shown. The numbers 
of xenografts in each subgroup are indicated in parentheses.
variability detected in this way were excluded from 
analysis.
RESULTS
Regions of increased sequence copy numbers 
were detected in 1 of 1 fibrosarcoma, in 3 of 12 
leiomyosarcomas (25%), in 10 of 22 liposarcomas 
(45%), in 10 of 16 MFHs (62%), and in 2 of 3 
malignant schwannomas (67%, Table 1), involving 
a total of 25 different chromosomal subregions 
(Fig. 1). As indicated in Table 2, the different am- 
plicons varied considerably in size. Also, the num­
ber of amplified regions detected for each individ­
ual sample was variable.
In total, 13 of the 54 soft tissue tumors (24%) 
showed amplifications at 12ql4. The amplicons 
were somewhat variable in size, however, and in 
some cases included, besides 12ql4, parts of band 
12ql 3 or 12ql5. Also, other regions of chromosome 
12 were amplified, although less frequently.
Amplicons covering 12q21, 12q21~q22, or 12q22 
were detected in three cases. Amplification of the 
12q24 band was detected in two MFH (MFH25 
and MFH43) and one malignant schwannoma 
(MS2X). The 12q21-q22 amplicon has previously 
been associated with WDLPS (Suijkerbuijk et al., 
1994a). Our present observations, however, sug­
gest that this amplification may not be specific for 
WDLPS only; it was also detected in one fibrosar­
coma (FSl), and one malignant schwannoma
(MS8/MS8X) (Table 2).
A region on the long arm of chromosome 1, 
Iq21-q22, also showed frequent increases in se­
quence copy numbers (Fig. 2). Although the dif­
ferent amplicons coinciding with this segment 
were somewhat variable in size, they showed a 
minimal region of overlap at Iq21-q22. Amplifica­
tion of this segment was observed in a total of 14














FSl Ip3l, 2q37, 4pl6, I2 q l4 ,
12q2l
LMS2 Iq 2 l-q 2 3 , I3q31
LMSI4 Iq 2 l-q 2 3 , I6 p ll-p l2
LMSI5 Iq21-q23
LS2 (wd) Iq 2 !-q 22 , I2 q l4
LS3x (pi) 1q 21-q22 Ip, 3
LS6 (wd) Iq 2 l—q22, Iq25, Iq32, I2 q l4
LS9 (wd) Iq 2 l-q 2 2 , 12q 14 4
LS 11 (wd) 1 2 q l3 -q l4 1
LS 13 (wd) Iq 2 l-q 2 2 , Iq25
LS2I (wd) Iq21-q22, I2 q (4 -q l5
LS22 (wd) I2 q l4 , I2q2l-q22
LS28/LS28x 6qter, 1 1 q 1 3 —q 14,
(pl/rc) I2 q l4 -q l5 ,  I5q2l~~q22
LS450I (wd) Iq 2 l-q 2 2 , Iq25, I2 q l4 - I5 ,  
I2q22
MFH3x 7q21 —q31, llq !4 , I2 q l4 8q
MFH8 IP
MFH 15 (pi) 8q22, 1 Iq 12
MFH 17 7q2l-qter, 8pl 1—p 12 iq
MFH 19 Iq 2 l-q 22/23, 3q26
MHF2I (pi) I4q24-qter, I5cen-ql5, 1 p, 7, 9q,
15q22-q26 18, 20
MFH36 lp ter-q 22 , 2q2l, 8q24, 
13q34
6p
MFH40 Iq 2 l-q 2 2 , I5q l2 -q l3 ,
17p 11~pl2, 18p 11.2, 18q21
7
MFH43 I2 q l3 - I4 ,  I2q24 4
MS2x 12q 14, 12q24
MS8/MS8X 1q 21—q22, I2 q l4 , I2q22
aFS, fibrosarcoma; LMS, leiomyosarcoma; LS, liposarcoma; MFH, malig­
nant fibrous histiocytoma; MS, malignant schwannoma. An x indicates a 
xenograft. For some of the LS and MFH, the subgroups are given in 
parentheses; wd, well differentiated; pi, pleomorphic; rc, round cell. The 
most frequently amplified regions are shown in boldface, in two cases, 
LS28/28x and MS8/8x, both primary and xenograft materials were ana­
lyzed. The amplification patterns were equal.
soft tissue sarcomas (26%), i.e ., at the same fre­
quency as the 12ql4 amplicon. T h e Iq21-q22 am­
plicon was detected in all (3 of 3) leiomyosarcomas 
with regional sequence copy number variations and 
in 3 of 14 osteosarcomas (Forus et al., 1995). A 
second amplicon on chromosome 1 (lq25) was ob­
served in 3 of 22 (14%) of the liposarcomas but not 
in any of the other soft tissue tumors examined.
4
DISCUSSION
Previous studies have convincingly dem on­
strated the usefulness of the CGH technique in the 
detection and mapping of D N A -sequence copy 
number changes in solid tumors (Kallioniemi et al.,
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Figure I. Chromosomal localization of DNA-sequence copy number increases in 54 soft tissue sarcomas 
as revealed by CGH. Only those chromosomes in which amplified regions were detected are represented. 
A vertical bar indicates an amplified region detected in a given tumor sample. The chromosomal band location 
of the amplicons was determined on the basis of DAPI banding patterns. Since high-resolution subband 
localization was not possible, the amplified regions may be smaller than indicated.
1992, 1994a; Suijkerbuijk et al., 1994a). CGH pro­
vides information not only on the overall occur­
rence of deletions or amplifications in a given tu­
mor but also on the size of the affected region
(Cher et al., 1994; Kallioniemi et al., 1994a),
Using CGH, we have detected and mapped re­
gions of amplification in 54 soft tissue sarcomas of 
various (sub)types. As a control, DNA extracted 
from peripheral blood samples of 10 healthy indi­
viduals was tested against the reference DNA. Re­
gions surrounding some of the centromeres showed 
an increased copy number in some of the samples. 
However, ratio changes at these sites could be de­
tected in only a minority of metaphases. Moreover, 
they never coincided with the chromosomal re­
gions we determined as amplified in the tumors 
(not shown).
Fifty-three of the fifty-four STS had previously 
been examined by Southern blot analysis for am­
plifications o f the 12ql4-linked genes MDM2,
CDK4, SAS, CHOP, GLI, and A2MR (Forus et al.,
1993, 1994). T h e present CGH analyses revealed 
increased DNA-sequence copy numbers in all o f  
the seven cases with known amplifications (LS6,
LSI 1, LS21, LS22, LS28/LS28x, F S l, and MS8/
MS8x; Table 2), as expected. We also detected 
amplifications involving 12ql4 in six additional 
cases, three liposarcomas (LS2, LS9, and LS4501), 
two malignant fibrous histiocytomas (MFH3x and 
MFH23), and one malignant schwannoma (MS2x). 
Only one of these, LS4501, was not included in the 
previous study (Forus et al., 1993).
In principle, Southern blot analyses are more 
sensitive than CGH (Kallioniemi et al., 1994a,b), 
and it is unlikely that in the previous studies (Forus 
etaL , 1993, 1994) amplifications of MDM2, CDK4, 
or other 12ql4-Iinked genes studied were missed. 
A role as a selective driver in these amplicons was 
previously assigned to the MDM2 or CDK4 gene 
(Oliner et aL, 1992; Forus et al., 1993, 1994; 
Khatib et ah, 1993). However, the present obser­
vations suggest that alternative explanations must
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Figure ?.. H/bridizncion of DNA from three different liposarcoma 
samples (in red) and normal femaie reference DNA (in green) to normal 
metaphase chromosomes. a,b: Two different metaphases hybridized 
with DNA from LS6. The three peaks in the lower panel (arrowheads) 
mark the Iq2l-q22, Iq25, and I q32 amplicons. Digitai images of a partial 
mecaphase spread including the two chromosome I homoiogs (upper 
panels) and a single straightened copy of chromosome I (middle panels) 
are shown. The amplicons are marked by arrows (upper panels) and 
arrowheads (middle panels), respectively. The lower panels show inte­
gration of fluorescence profiles along the chromosome I homoiog de­
picted in the middle panels. The measured intensity profiles are depicted 
in red (tumor D N A) and green (normal D N A ) lines, respectively. The 
blue lines represent the CGH profile, i.e., the red-to-green fluorescence 
ratios along the whole chromosome length, c: A  metaphase hybridized 
with D N A  from LS3x, showing overrepresentation of the whole I p arm 
and the Iq2 l~q22 segment (arrowheads), d: A  metaphase hybridized 
with D N A  from LS2I, showing the Iq2l--q22 amplicon (arrowheads),
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be considered, at least for a subset of tumors. In 
this light, amplification of more than one gene 
could be important, e.g., MDM2, because its gene 
product can inactivate p53 (Momand et al., 1992; 
Oliner et al., 1992), and CDK4, because of its pos­
sible role in the regulation of pRB activity (Hinds 
et al., 1992). However, the simplest explanation 
might be that the 12ql4 amplicons are selected by 
a common mechanism driven by an as yet hypo­
thetical gene, as suggested previously (Forus et aL, 
1993). Our future studies will be aimed at the iden­
tification of such a gene(s).
Interestingly, the CGH analyses also revealed a 
novel major region of amplification in human sar­
comas, namely, Iq21-q22 (Fig. 2). Increased se­
quence copy numbers coinciding with the 1 q21— 
q22 segment were observed in a total of 14 soft 
tissue sarcomas (26%; Table 2) and were also de­
tected in 3 of 14 osteosarcomas (Forus et ah, 1995). 
Interestingly, the lq21-22 amplicon was not ob­
served in breast cancer (Kallioniemi et al., 1994a), 
prostate cancer (Cher et al., 1994), or malignant 
gliomas (Schröck et al., 1994), nor has it previously 
been associated with the development or progres­
sion o f human sarcomas. Conceivably, the 1 q21— 
q22 region harbors genes important for human sar­
coma development and/or progression. Several 
potentially interesting genes have been mapped to 
this region, including the octamer-binding tran­
scription factor OTFl (Iq22-q25) and several 
members of the S-100 family of calcium-binding
proteins, e .g ., CACY and CAPL (Iq21-q25; En- 
gelkamp et al., 1993; Dracopoli et al., 1994). N o ­
tably, overexpression of the CACY gene has been 
associated with metastatic behavior of human mel­
anomas (Weterman et al., 1992), and amplification 
of the gene has been detected in some melanoma 
cell lines.
T h e  most frequently observed amplicons, 1 q21— 
q22 and 12ql4, were unevenly distributed among 
the different STS subgroups. We detected both 
amplicons in six samples, including five well-dif­
ferentiated liposarcomas (LS2, LS6, LS9, LS4501, 
and LS21). Fifteen additional samples showed am­
plification of either Iq21-q22 or 12q 14. However, 
there was no clear correlation between the pres­
ence of either Iq21-q22 or 12ql4 or both ampli­
cons and any known clinical parameters (not 
shown). Therefore, it is difficult to establish the 
biological consequences of the various combina­
tions. T h e  overall occurrence of DNA amplifica­
tion was considerably lower in leiomyosarcomas 
(25%) than in other STS subgroups, i.e., liposar­
comas (47%) and M FH (59%), showing that other
(genetic) mechanisms may be more important for 
the former group of sarcomas. However, the three 
leiomyosarcomas with detectable amplifications
(LMS2x, LMS14, and LMS15; Table 2) all showed 
involvement of Iq21~q22, whereas neither the pre­
vious molecular analysis of 12ql4-linked (onco­
g e n e s  (Forus et al., 1993,1994) nor the CGH anal­
ysis described here detected 12ql4 amplifications. 
T hese observations indicate that a gene in 1 q21— 
q22 may play an important role in the development 
of at least a subset of leiomyosarcomas.
Our CGH analyses revealed other amplified re­
gions as well. However, most of them were also 
detected in other tumor types (Cher et al., 1994; 
Kallioniemi et al., 1994a) or were present at rela­
tively low frequencies (in one or two of the sam­
ples). Amplified regions observed in a large num­
ber of tumors are more likely to harbor relevant 
oncogenes, since one expects genes of importance 
for malignant development to be repeatedly acti­
vated (or aberrated). Thus, we consider these latter 
amplifications less significant for the processes 
leading to STS.
Although the CGH technique is very well suited 
for the detection and mapping of DNA-sequence 
copy number changes, especially amplifications, 
one should be aware of its limitations. For exam­
ple, CGH may fail to detect low-level copy number 
changes involving small chromosomal regions. 
CGH analysis of breast cancer cell lines with 
known amplifications of ERBB2  and BCL1, forex- 
ample, revealed increased sequence copy numbers 
at the respective loci (17ql2 and l lq l3 )  in only two 
of three of the cases (Kallioniemi et al., 1994a). All 
high-level amplifications (5-15-fold) were de­
tected, whereas those at lower levels (2-5-fold) 
were missed. In fact, it was later reported that the 
total length of amplified DNA  has to be at least 2 
Mb for detection by CGH (Kallioniemi et al., 
1994b, and references therein). Thus, the actual 
amplification frequencies, especially for the 
smaller amplicons, may be significantly higher than 
those reported here. A more complete overview of 
genetic alterations in a given panel of tumors can 
be obtained by combining CGH analysis with in­
terphase FISH and molecular analysis using spe­
cific probes targeting the regions highlighted by 
CGH. Such studies are currently in progress.
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